Pharma Exclusives Pressreleases
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Thursday, February 13, 2025Allergan Aesthetics an AbbVie company today announced Allergan Medical Institute AMI will open three new stateoftheart training centers in the US expanding access to highquality tailored training to licensed aesthetics providers AMIs unique curriculu...
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Thursday, February 13, 2025Kiora Pharmaceuticals Inc announced that the US Patent and Trademark Office has issued a compositionofmatter patent USB on a specific crystalline form or polymorph of KIO KIO is a novel nonsteroidal antiinflammatory small molecule inhibitor of dihydr...
Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve
Wednesday, February 12, 2025Prenetics Global Limited a leading genomics and consumer healthcare company today announced a groundbreaking genomicsbased partnership with Humanity Protocol a decentralized identity verification company This collaboration leverages Prenetics advance...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Wednesday, February 12, 2025AbbVieand Xilio Therapeutics Inc a clinicalstage biotechnology company discovering and developing tumoractivated immunooncology therapies for people living with cancer today announced a collaboration and optiontolicense agreement to develop novel tum...
Pfizer and Astellas Report Long-Term Effectiveness of PADCEV® and KEYTRUDA® in First-Line Treatment of Advanced Urothelial Cancer
Tuesday, February 11, 2025These latest findings from the EV trial reaffirm the primary results which demonstrated survival improvements for patients treated with enfortumab vedotin and pembrolizumab that were previously unprecedented in locally advanced or metastatic urotheli...
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Friday, February 07, 2025Allergan Aesthetics an AbbVie company announced a nationwide open casting call in search of the next Faces of Natrelle encouraging women who have experienced breast reconstruction andor augmentation to share their inspiring stories and be featured in...
Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
Thursday, February 06, 2025Allergan Aesthetics an AbbVie company is continuing its dedication to the LIMITLESS initiative by expanding the content of its Presidential Series through indepth interviews with Dr Caroline Glicksman Immediate Past President of The Aesthetic Foundat...
Merck Begins Phase 3 waveLINE-010 Trial to Assess Zilovertamab Vedotin for Untreated Diffuse Large B-Cell Lymphoma
Thursday, February 06, 2025Merck known as MSD outside of the United States and Canada today announced the initiation of waveLINE a pivotal Phase clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide doxorubicin and prednisone RCHP...
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata
Wednesday, February 05, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the launch of the international CorEvitas Adolescent Alopecia Areata AA Registry addressing a critical unmet need for realworld adolescentspecific evidence
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Monday, February 03, 2025Pfizer Inctoday announced positive topline results from the progressionfree survival PFS analysis of the Phase BREAKWATER study of BRAFTOVI encorafenib in combination with cetuximab marketed as ERBITUX and mFOLFOX fluorouracil leucovorin and oxalip...
